spacer
home > white papers > The Importance of ADCC in Assessing Clinically Relevant Differences - Sartorius Stedim BioOutsource Ltd
WHITE PAPERS

Sartorius Stedim BioOutsource Ltd

phone +44 (0)141 946 4222
web http://www.biooutsource.com
email 1 Technology Terrace, Todd Campus, West of Scotland Science Park, Glasgow, G20 0XA, UK

The Importance of ADCC in Assessing Clinically Relevant Differences

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
The Importance of ADCC in Assessing Clinically Relevant Differences
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

PCI’s Tredegar Site Announces Significant Expansion of Analytical Laboratories at its Center of Excellence for Contained Manufacturing

Philadelphia, USA- March 19, 2018. Global pharmaceutical outsourcing services provider PCI Pharma Services (PCI) is pleased to announce a laboratory expansion at its site in Tredegar, Wales, UK. 
More info >>


White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>


Industry Events

3rd Annual Inhalation & Respiratory Drug Delivery Congress

8-9 May 2018, London, UK

Oxford Global are proud to present our hugely popular 3rd Annual Inhalation & Respiratory Drug Delivery Congress, 8th – 9th May 2018, London, UK. Over 300 delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will gather for over 20 presentations and case studies focused on the key issues in inhalation and respiratory drug delivery.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement